Navigation Links
MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
Date:9/11/2008

GAITHERSBURG, Md. and TOKYO, Sept. 11 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune has global rights to any resulting product candidates and will be responsible for preclinical and clinical development, as well as all future development, manufacturing, sales and marketing activities.

"It's an honor to work with Ken-ichi Arai, founder of SBI Biotech and one of Japan's leading scientists. We look forward to collaborating with him and his organization as we develop potential new treatments for autoimmune diseases such as SLE," said Anthony J. Coyle, Ph.D., vice president, research, respiratory, inflammation and autoimmunity. "As an innovative company dedicated to making a difference for patients, MedImmune will continue to seek out research and development initiatives that may address some of society's critical unmet medical needs."

Under the terms of the agreement, MedImmune is to provide SBI Biotech with an undisclosed upfront payment, milestone payments and royalties on future marketed products. SBI Biotech has granted MedImmune an exclusive license to research, develop and commercialize products that target the ILT7 protein. In addition, MedImmune will have the option to license additional targets resulting from SBI Biotech's research activities.

"We are pleased to collaborate with MedImmune, a company with strong capabilities to develop therapeutic antibodies including expertise in humanization and large-scale production. MedImmune is an excellent company and this agreement facilitates the research and development of an anti-ILT7 antibody," said Ken-ichi Arai, M.D. and Ph.D., president & CEO, SBI Biotech. "We have been seeking other potential targets for treatments of autoimmune diseases and cancer and will continue further research and development. We are confident that the collaboration with MedImmune will greatly strengthen the potential for our program."

About ILT7

ILT7 is a cell surface protein uniquely expressed on plasmacytoid dendritic cells (pDC). Targeting ILT7 offers potential to treat autoimmune diseases because pDCs are believed to be critical in the development of autoimmune diseases such as systemic lupus erythematosus.

About MedImmune

MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune's website at http://www.medimmune.com.

About SBI Biotech Co., Ltd.

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at http://www.sbibiotech.jp.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
2. MedImmune Expands Scientific and Engineering Leadership
3. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
4. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
5. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
6. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
7. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
8. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
9. Further Acquisition for Schofield Media Group LLC
10. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
11. Area Women Gather in Milford on July 10 to Further the Mission of Womens Caring Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... In just two days, Aqua Design ... garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the original ... (and counting) already backing the campaign. , “We are very grateful for ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June ... ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present on: ... of cases litigated under ERISA involve claims for long-term disability benefits. This ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... 24, 2017 , ... “Finding Christ Through Social Media: Year ... chronicling the writer’s path toward true communion with God. “Finding Christ Through Social ... the creation of published author Lea Michelle Johnson, a follower of Christ, wife ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary ... Medical cannabis products around ... Research, Inc., projects that the global medical cannabis market will reach a ... is a major market for the new growing industry. By the ... to legally buy and sell medical cannabis. More conservative states like ...
(Date:3/24/2017)... Research and Markets has announced the addition ... - 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics ... the growing market of deep learning solutions within the healthcare domain. ... emerged as a novel solution to generate relevant insights from medical ...
(Date:3/24/2017)... 2017 Global Ampoules Market report ... classifications, applications and industry chain structure. The Ampoules market ... history, competitive landscape analysis, and major regions, development status. ... ... pages providing 10 company profiles and 183 tables and ...
Breaking Medicine Technology: